SolasCure enrols first patient in a next phase II clinical trial to advance Aurase Wound Gel

FHS
March 17, 2025
11:36 am

SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today announced the initiation of a new Phase II clinical trial, CLEANVLU2.

Park runs boost life satisfaction and save money by improving well-being

Park runs improve life satisfaction, especially for the least active, while providing significant economic benefits through cost-effectiveness.

October 7, 2024

Study reveals the possibility of a laboratory origin of COVID-19

The origin of COVID-19 is highly debated – most studies have focused on a zoonotic origin, but research from the journal Risk Analysis, examined the

March 15, 2024

Are ultraprocessed foods putting your child’s heart at risk?

Associations between ultra-processed food (UPF) consumption and cardiometabolic risk factors in young children.

May 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.